Integrative network pharmacology and genomic analysis of esculin targeting PARP1 in cervical cancer: Insights from ADME profiling, molecular docking, and biomarker discovery
- 8 July 2026
- journal article
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 124 (Pt 2) , 109244
Abstract
No abstract availableKeywords
Funding Information
- Bharathiar University (CMRG250625)
This publication has 30 references indexed in Scilit:
- Investigations on bioactive compounds of Punica granatum and Beta vulgaris for breast cancer treatment: Network pharmacology predictions, molecular docking, and in-vitro experimental verification of radiation-sensitizing effectsComputational Biology and Chemistry, 2025
- Therapeutic role of naringin in cancer: molecular pathways, synergy with other agents, and nanocarrier innovationsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Toxicity of Bromo-DragonFLY as a New Psychoactive Substance: Application of In Silico Methods for the Prediction of Key Toxicological Parameters Important to Clinical and Forensic ToxicologyChemical Research in Toxicology, 2024
- Early-stage biomarkers identification by integrated genomic analysis in Hepatocellular carcinomaMedicine in Omics, 2024
- Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapyMolecular Biology Reports, 2024
- The exoprotein Gbp of Fusobacterium nucleatum promotes THP-1 cell lipid deposition by binding to CypA and activating PI3K-AKT/MAPK/NF-κB pathwaysJournal of Advanced Research, 2023
- The pharmacological and pharmacokinetic properties of esculin: A comprehensive reviewPhytotherapy Research, 2022
- Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrestBreast Cancer Research and Treatment, 2022
- PARP mediated DNA damage response, genomic stability and immune responsesInternational Journal of Cancer, 2021
- Cervical cancerThe Lancet, 2019